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Abstract
In pulmonary hypertension (PH), right ventricular (RV) performance determines survival. Pulmonary artery (PA) stiffening is an
important biomechanical event in PH and also predicts survival based on the PA relative area change (RAC) measured at rest using
magnetic resonance imaging (MRI). In this exploratory study, we sought to generate novel hypotheses regarding the influence of
stress RAC on PH prognosis and the interaction between PA stiffening, RV performance and survival. Fifteen PH patients under-
went dobutamine stress-MRI (ds-MRI) and right heart catheterization. RACREST, RACSTRESS, and RAC (RAC STRESS – RAC REST)
were correlated against resting invasive hemodynamics and ds-MRI data regarding RV performance and RV-PA coupling efficiency
(n’vv [RV stroke volume/RVend-systolic volume]). The impact of RAC, RV data, and n’vv on ten-year survival were determined using
Kaplan–Meier analysis. PH patients with a low RAC (<2.6%) had a worse long-term survival (log-rank P¼ 0.045, HR for
death¼ 4.46 [95% CI¼ 1.08–24.5]) than those with RAC2.6%. Given the small sample, these data should be interpreted
with caution; however, low RAC was associated with an increase in stress diastolic PA area indicating proximal PA stiffening.
Associations of borderline significance were observed between low RACSTRESS and low n’vvSTRESS, Z’VV, and RVEF. Further
studies are required to validate the potential prognostic impact of RAC and the biomechanics potentially connecting low RAC
to shorter survival. Such studies may facilitate development of novel PH therapies targeted to the proximal PA.
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Pulmonary arterial hypertension (PAH) results from
obstructive or obliterative disease within the small resistance
vessels of the lung. Chronic thomboembolic pulmonary
hypertension (CTEPH) results from unresolved clot in the
major pulmonary vessels. Various hemodynamic variables
predict adverse clinical outcomes in both forms of pulmon-
ary hypertension (PH). These most frequently include data
which reﬂect RV performance, such as RV stroke volume,1
mixed venous oxygen saturation (MvO2),
2 and serum N
terminal-pro brain natriuretic peptide (NT-proBNP) con-
centration.3 The prognostic value of hemodynamic pressure
measurements have proven less consistent in past studies,
either as mean pulmonary artery pressure (mPAP),4–6
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which reﬂects the constant component of RV afterload, or
PA pulse pressure,7 which is more indicative of pulsatile
load. This has led investigators to seek alternative mechan-
isms by which RV failure evolves in patients with PH, in the
hope that compensatory treatments can be introduced to
arrest this event.
PH is commonly associated with pathological stiﬀening
of the proximal pulmonary arteries (PA), a process that is
known to further impair RV performance.8 The basic mech-
anism(s) responsible for PA stiﬀening in PH are complex
and will depend upon several biomechanical factors includ-
ing the PA wall thickness and the non-linear dependence of
the PA elastic modulus on blood pressure.4,9 PA pressure
will in turn be determined by RV stroke volume and RV
afterload. Given these complexities, interactions between
PA stiﬀening, RV performance, and outcome should ideally
be studied using invasive hemodynamic methods, combined
with volumetric data from MRI. However, it is diﬃcult to
conduct these studies in patients with PH. Moreover, recent
data demonstrate that MRI, used alone, can be used to
accurately assess both PA stiﬀening, via the PA relative
area change (RAC),10 and the eﬃciency of coupling between
the RV and PA, using the ratio of RV stroke volume over
RV end-systolic volume (SV/ESV, also termed Z’VV),
11
although the accuracy of this approximation is still the sub-
ject of some debate.
RAC is deﬁned as the ratio of the change in PA area
during the cardiac cycle (AMAX – AMIN) over the PA area
at either diastole (AMIN) or systole (AMAX). Gan et al.
recently demonstrated a negative curvilinear relationship
between RAC and mean PAP measured at rest in PH
patients.12 They also demonstrated that patients with a
low resting RAC (16%) had a poorer prognosis, a ﬁnding
that was later corroborated by Swift et al.13 This later study
also demonstrated that abnormal RAC could be detected
even in PH patients with early disease, as characterized by
a mild elevation in PVR (<4 Woods Units [WU]) and
normal RV function. This suggests a potential role for
RAC as a risk stratiﬁcation biomarker,13 perhaps facilitat-
ing treatment intensiﬁcation in appropriate patients.
In the current study, we sought to generate novel hypoth-
eses regarding the inﬂuence of stress RAC on PH prognosis
and the interaction between PA stiﬀening, RV performance,
and survival. A recent study by Sharma et al. illustrates that
stress testing can reveal additional predictive information to
studies performed at rest. Using dobutamine-stress echocar-
diography, this group was able to accurately detect sub-
clinical reductions in RV contractile reserve using a stress
protocol similar to the current study.8 Our approach was to
measure RAC at rest and stress using MRI in a small cohort
of PH patients. Long-term follow-up in a national PH
center provided prognostic information. We chose MRI
over echocardiography because of its superior tissue con-
trast, higher spatial resolution, and ability to image the
PA at any angle, making it the recommended modality for
this purpose.14
Methods
Study participants
Fifteen participants were recruited during elective inpatient
assessment for suspected PH at the Western Inﬁrmary (now
Queen Elizabeth University Hospital), Glasgow, UK,
between August 2004 and July 2005. All underwent a stand-
ard series of diagnostic tests, including right heart catheter-
ization,15 in addition to dobutamine stress-MRI (ds-MRI).
Five younger volunteers underwent ds-MRI alone. All par-
ticipants gave informed written consent to a study protocol
that had been approved by the West of Scotland Research
and Ethics Committee. Exclusion criteria included contra-
indications to MRI, e.g. claustrophobia, metal implants or
foreign bodies, and contraindications to dobutamine, e.g.
aortic stenosis, hypokalemia, and dobutamine allergy. No
participants were taking chronotropic medication at the
time of MRI and no patients had received any disease-
targeted therapy for PH.
Follow-up and survival
All cases were followed up at a national PH center. The
frequency of clinic visits was dependent on clinical progress
and varied between one and six months. Survival informa-
tion was retrieved retrospectively from a prospectively
populated database. This was calculated, in days, from the
date of right heart catheterization to death or the date of
database review in surviving patients. Patients were
excluded from survival analyses if an explicitly unrelated
cause of death was recorded.
MRI examination
All studies were performed on a 1.5 T MRI scanner (Sonata
Magnetom, Siemens, Germany) using an identical protocol
in patients and younger volunteers. In PH patients, all scans
were performed within 48 h of right heart catheterization.
Prior to ds-MRI, all participants were weighed to allow
calculation of a dobutamine infusion rate (see the
‘‘Dobutamine Infusion’’ subsection). The dobutamine infu-
sion was connected (but not started) and a brachial artery
sphygmomanometer and three-lead ECG monitoring were
attached before the participant was moved inside the
magnet.
Baseline measurements. Baseline MRI measurements were
recorded as previously reported.16,17 MR velocity ﬂow map-
ping was used to determine RV stroke volume (RVSV) from
ﬂow in the main PA. Flow maps were planned perpendicular
to the target vessel in a double-oblique plane, at least 1.5 cm
distal to the pulmonary valve. A velocity-encoded k-space
segmented gradient-echo sequence was used (imaging par-
ameters: echo time/repetition time [TE/TR]¼ 3.1/16ms, ﬂip
angle [FA]¼ 15, slice thickness¼ 6mm, temporal reso-
lution¼ limited by TR, image matrix¼ 256, ﬁeld of view
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[FOV]¼ 380mm, in-plane resolution¼ 1.9 1.5mm, vel-
ocity encoding range¼ 150 cm/s) to generate 45 matched
pairs of anatomical and velocity images. TrueFISP cine
images of the main PA were then acquired utilizing copied
sliced positions from the ﬂow map sequence. Retrospective
ECG-gating was used to ensure coverage of the complete
cardiac cycle. Participants were instructed to breathe freely
throughout this section of the protocol. The average acqui-
sition time was 2–3min.
Dobutamine infusion. Dobutamine was administered using
a digital syringe driver loaded with a 50-mL syringe contain-
ing 50mg of dobutamine hydrochloride (Posiject,
Boehringer Ingelheim) diluted in 0.9% saline. The syringe
driver was located in the control room, away from the
magnet, and attached to the participant by a length of
tubing fed through a wave-guide conduit. The infusion
was started at 5mcg/kg/min and increased in 5mcg
steps every 5min to achieve the maximum tolerated
dose, up to a ceiling of 20mcg/kg/min. Heart rate,
symptoms, and a three-lead ECG trace were monitored
throughout and systemic BP was measured at every
3-min interval. The following predeﬁned criteria were
used as triggers to defer any further increase in dobutamine
dose, and if persistent prompt a 5mcg/kg/min reduction in
infusion rate: (1) rise in HR> 50%; (2) fall in systolic
BP> 20%; (3) intolerable side-eﬀects or participant’s
request.
Stress measurements. Stress measurements were initiated once
the maximum tolerated dose of dobutamine had been
reached and a steady state had been achieved (i.e. after at
least 3min on this dose). No speciﬁc alterations were made
to the imaging protocol for stress imaging. However, the
velocity-encoding gradient was modiﬁed to accommodate
higher stroke volume velocities (maximum 300 cm/s) in
approximately half of the PH patients and all of the younger
volunteers.
MRI analysis
All images were analyzed by a single experienced operator
(KGB) using the Argus analysis software (Siemens,
Germany). Scans were coded by number and analyzed in
batches. KGB was blinded to the identity and hemodynamic
results of the patients. A second experienced operator (GJ)
contoured the MPA at rest and stress to provide inter-
observer data for RAC. GJ was blinded to all clinical
data and KGB’s results.
Pulmonary artery area and determination of relative area
change. Maximum PA area (AMAX) and minimum PA area
(AMIN) were measured at rest (AMAXREST and AMINREST)
and stress (AMAXSTRESS and AMINSTRESS) on ds-MRI
images by manual planimetry using Osirix for Mac v5.8
(Pixmeo, Bernex, Switzerland). Example images are shown
in Fig. 1. The change in AMAX (AMAX) and AMIN
(AMIN) between rest and stress were calculated as
Fig. 1 Representative MRI images of the main pulmonary artery (MPA) acquired at rest (a, b) and at stress (c, d) in PH patient 1. The intima
of the MPA was manually contoured at all time points using Osirix for Mac v5.8 (Pixmeo, Bernex, Switzerland) allowing measurement of the
minimum PA area (AMIN (a, c)) and maximum PA area (AMAX (b, d)). These data were used to calculate RACREST, RACSTRESS, and RAC, which
were 12%, 9%, and 3% for this patient, respectively.
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(AMAXorMINSTRESS – AMAXorMINREST). RAC at rest
(RACREST) and RAC during stress (RACSTRESS) were cal-
culated as RAC¼ (AMAX – AMIN)/AMIN, using PA meas-
urements recorded under appropriate conditions, as in
earlier publications. The change in RAC between rest and
stress (RAC) was calculated as (RACSTRESS – RACREST).
Right ventricular volume, ejection fraction, and RV-PA
coupling. Planimetry of selected short axis images was used
to measure RV volumes as described previously.18 Each
value was indexed against body surface areas and is reported
as RV end-diastolic volume index (RVEDVI), RV end-
systolic volume index (RVESVI). Velocity encoded ﬂow
maps were analyzed to determine RVSV at rest and during
stress using techniques described in earlier publications.10
The Argus analysis software was utilized, including back-
ground subtraction to correct for velocity measurement
error (or ‘‘baseline drift’’) by assessing a region of zero ﬂow
at each point in the cardiac cycle. Prior to analysis, each
image set was inspected to verify accurate depiction of the
target vessel and the absence of artefacts including aliasing on
the velocity images. The software automatically computed
the ﬂow rate (in mL/s) during each time point within the
target vessel. These data were integrated with the area of
the target vessel and the positive values summed to produce
RVSV. These values were indexed against body surface area
to compute RV stroke volume index (RVSVI). Right ven-
tricular ejection fraction (RVEF (%)) was determined as
(stroke volume/end-diastolic volume) 100. Changes in RV
volumes, RVEF, and heart rate between rest and stress were
calculated as a percentage (e.g.RVSVI¼ ((RVSVISTRESS –
RVSVIREST)/RVSVIREST) 100).
RV-PA coupling eﬃciency is most accurately described
by the ratio maximal systolic ventricular elastance (Emax,) to
eﬀective arterial elastance (Ea), with these data being mea-
sured invasively. However, Sanz et al. recently demonstrated
that Emax/Ea can be approximated non-invasively using
the parameter Z’VV, which is the ratio of RV stroke
volume/RV end-systolic volume, measured by MRI.11
Previous studies demonstrated that optimal ventriculo-
arterial coupling occurs when Emax/Ea (or the non-invasive
equivalent Z’VV) is close to unity,
19 with lower values occur-
ring in pulmonary vascular disease.11,20 Z’VV was deter-
mined in the current study as RV stroke volume/RV
end-systolic volume. In the current study, the change in
Z’VV between rest and stress (Z’VV) was calculated as
(Z’VVSTRESS – Z’VVREST).
Statistics
A sample size calculation indicated that 15 paired observa-
tions in PH patients were required to reliably detect a reduc-
tion in median RAC in the PH group of at least 28% using
the Wilcoxon matched-pairs signed rank test, assuming a
one-sided a¼ 0.05 and 80% power. This calculation used
data on resting RAC collected in healthy controls and
patients with Acquired Immunodeﬁciency Syndrome
(AIDS) and observed proximal PA stiﬀening and RV
remodeling on MRI.21 These data were chosen because no
stress data had been reported when the study was designed.
Echocardiographic systolic PAP estimates were only avail-
able in 5/13 AIDS patients reported in this study (mean
systolic PAP¼ 40.4 (25) mmHg) but the observed MRI
abnormalities were consistent with elevated RV afterload,
likely associated with Human Immunodeﬁciency Virus
(HIV)-associated pulmonary vascular disease.21 Given the
small sample size, non-parametric tests were used where
possible. All values are presented as median (interquartile
range) unless otherwise stated. In PH patients, comparisons
between resting and stress MRI measurements were made
using the Wilcoxon matched-pairs signed rank test. Since
this test cannot be used in samples smaller than six, the
paired t-test was used for these comparisons in the younger
volunteer population and in comparisons of measurements
in low and high RAC subgroups. Correlation was assessed
using Spearman’s rho test and P values were adjusted by
Bonferroni’s method (0.05/number of comparisons).
Agreement between MRI reporters regarding RAC in PH
patients was assessed using the intraclass correlation coeﬃ-
cient (ICC, two-way mixed eﬀects model). The PH popula-
tion was dichotomized either side of the median values of
RACREST, RACSTRESS, and RAC. Kaplan–Meier mortal-
ity curves were generated for these dichotomized groups and
any inequalities in mortality rates were assessed by log rank
testing. Diﬀerences in the risk of death between groups were
quantiﬁed by hazard ratios (95% conﬁdence interval [CI]).
Diﬀerences in RV parameters or hemodynamic measure-
ments within each group were assessed using the Mann–
Whitney test. All statistical analyses were performed using
GraphPad Prism 6 for Mac (GraphPad, San Diego, CA,
USA) or SPSS v.22 (SPSS, Chicago, IL, USA). All tests
were two-sided and assumed a signiﬁcance level of 0.05.
Results
Population demographics and clinical findings
PAH or CTEPH was conﬁrmed in all 15 patients. Clinical
and hemodynamic results for this cohort are summarized in
Table 1. The ﬁve volunteers were all men, had no history of
cardiorespiratory disease, and were signiﬁcantly younger
than PH patients (median age¼ 33 years, age range¼
31–49 years; PH patients: median age¼ 54 years, age
range¼ 45–60 years; P¼ 0.013). Seven of 12 PH patients
died over the follow-up period. The median survival time
was 3045 days. Patient 7 (see Table 1) was excluded from
long-term survival analyses having died from surgical com-
plications directly related to attempted pulmonary endarter-
ectomy (PEA). No other patients with CTEPH were referred
for PEA.
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Dobutamine dose and symptoms
There were no serious adverse events and all participants
completed the study. Of the 15 PH patients, ﬁve experienced
breathlessness, one reported light-headedness, and one
reported headache. None of these symptoms were intoler-
able or necessitated a reduction in dobutamine dose.
Excessive tachycardia (>50% of resting HR) necessitated
a reduction in the dobutamine dose to 15mcg/kg/min in
4/15 patients (patients 3, 7, 8, and 9) before stress-MRI
was initiated. The maximum tolerated dose was, therefore,
20mcg/kg/min in 11 patients and 15mcg/kg/min in four
patients.
Pulmonary artery area and RAC
Data are described in detail in Table 2. AMIN REST was
signiﬁcantly larger in PH patients (median¼ 8.3 cm2,
range¼ 5.9–10.4 cm2) than in younger volunteers (med-
ian¼ 5.2 cm2, range¼ 3.6–5.7 cm2; P¼ 0.0037). Similarly,
AMAX REST was larger in PH patients (median¼ 9.3 cm2,
range¼ 7.3–11.4 cm2) than younger volunteers (med-
ian¼ 6.8 cm2, range¼ 5.9–7.9 cm2; P¼ 0.0499). RACREST
was signiﬁcantly lower in PH patients (12.6%
[range¼ 9.4–19.2%]) than in younger volunteers (43.6%
[range¼ 33.1–74.6%]; P¼ 0.0001).
In 2/15 PH patients, the stress MPA cine images were
signiﬁcantly degraded by cardiac motion artefact. Data
from 13/15 patients were therefore available for analyses.
These data are presented in detail in Table 2. In 11/13 PH
patients, AMIN increased (i.e. AMIN was positive).
As a result, there was a small but statistically signiﬁcant
increase in median AMIN during stress (8.2 [5.9–9.9] cm
2 to
8.3 [6.0–10.7] cm2; P¼ 0.0034). AMAX was also posi-
tive in 11/13 patients and median AMAX also increased
by a small but signiﬁcant amount (9.3 [7.1–11.0] cm2
to 9.6 [7.2–11.5] cm2; P¼ 0.025). Median RACSTRESS
(12.8 [10.4–19.8]%) was not diﬀerent from median
RACREST (10.8 [9.1–16.0]%); P¼ 0.626), since the inter-
quartile range of RAC traversed zero (median
RAC¼ [2.1 (6.4 – 4.4)%]). This was likely due to sig-
niﬁcant heterogeneity in the eﬀect of stress on RAC in PH
patients, with increments seen in some patients and decre-
ments in others (see Fig. 2).
In younger volunteers, there was a trend towards a reduc-
tion in median AMIN and increment in AMAX, but this was
not statistically signiﬁcant. There was, however, evidence of
increased RAC during stress (RACREST¼ 44 [33–75]%,
RACSTRESS¼ 68 [29–85]%; P¼ 0.0112). Contrary to PH
patients, RAC was positive in all younger volunteers
with no heterogeneity and median RAC was higher in
younger volunteers (þ22.9 [12.7–33.9]%) than in PH
patients (2.1 [6.4 – 4.4]%; P¼ 0.0002), see Fig. 2.
Inter-observer variability of RAC measurements
There was no statistically signiﬁcant diﬀerence between
median RAC measured in PH patients by Operators 1
and 2 (2.6% versus 0.31%; P¼ 0.436) and these
data showed good correlation (r¼ 0.731, P¼ 0.006).
Table 1 Clinical and hemodynamic results in 15 patients with PH.
Patient
Age
(years) Sex Diagnosis
NYHA
class
mPAP
(mmHg)
CI
(L/min/m2)
PVR
(mmHg/L/min)
RAP
(mmHg)
MVO2
(%)
PCWP
(mmHg)
NT-proBNP
(ng/L)
1 62 F CTEPH III 49 2.1 10 5 60 8 3870
2 45 F iPAH III 49 1.6 16 9 n/a 4 669
3 51 F PAH-CTD III 49 2.4 12 5 72 7 126
4 43 F PAH-CTD III 53 3.3 9 2 60 8 803
5 45 F CTEPH III 45 3.6 7 1 70 5 254
6 56 F PAH-CTD III 58 1.7 18 6 63 7 2715
7 67 M CTEPH III 42 2.3 8 5 61 8 1544
8 60 F iPAH III 65 1.6 23 7 63 6 852
9 54 M iPAH II 51 2.5 8 9 n/a 10 40
10 59 M iPAH II 30 2.3 7 5 68 8 106
11 74 F CTEPH III 69 2.5 14 2 64 10 n/a
12 50 F PAH-CTD III 43 2 12 13 53 5 4672
13 54 F iPAH III 47 2.5 8 8 76 11 81
14 38 F iPAH II 25 2.2 7 2 58 n/a 33
15 56 M CTEPH III 79 1.9 19 18 61 7 1641
CTEPH, chronic thrombo-embolic PH; iPAH, idiopathic pulmonary arterial hypertension; PAH-CTD, PAH related to connective tissue disease; PAP, pulmonary
artery pressure; CI, Cardiac Index; PVR, pulmonary vascular resistance; RAP, right atrial pressure; MVO2, mixed venous oxygen saturation; PCWP, pulmonary
capillary wedge pressure; NT-proBNP, N terminal pro-B type natriuretic peptide.
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The variance of the data appeared similar (Operator 1
SD¼ 6.6, Operator 2 SD¼ 7.2). There was good intra-
observer agreement between operator regarding RAC
(ICC¼ 0.862 [0.570–0.957], P¼ 0.001). The level of
agreement was superior for RACREST 0.900 ([0.690–0.969];
P< 0.001) relative to RACSTRESS (0.864 [0.46–0.961];
P< 0.001).
RV measurements and RV-PA coupling (’VV)
As shown in Table 2, Z’VVREST was signiﬁcantly lower in
PH patients (0.62 [0.24–0.79]) than in younger volunteers
(1.69 [1.071–2.03], P¼ 0.0005), in whom it exceeded unity.
In PH patients, there was evidence of RV systolic dysfunc-
tion, with statistically signiﬁcant diﬀerences in RVSVI,
RVEF, and RVESVI, relative to younger volunteers. All
RV measurements were normal in volunteers.
In PH patients, Z’VV increased signiﬁcantly with dobuta-
mine stress (median Z’VV: þ0.2, P< 0.001), but median
Z’VV STRESS remained below unity (0.8). Dobutamine
stress resulted in a statistically signiﬁcant fall in RVESVI
(median RVESVI¼14mL, P¼ 0.0353) and increment
in RVEF (median RVEF¼þ6%, P¼ 0.0181). Cardiac
index (CI) increased signiﬁcantly (median CI¼þ0.8L/
min/m2, P¼ 0.0001), but since RVSVI did not change
(median RVSVI¼þ3mL, P¼ 0.208) this was mediated
purely by increased HR (median HR¼þ39 beats per
minute [bpm], P< 0.0001).
In younger volunteers, dobutamine resulted in signiﬁ-
cantly increased Z’VV (median Z’VV¼þ3.2, P¼ 0.004),
RVSVI (median RVSVI¼þ5mL, P¼ 0.0312), RVEF
(median RVEF¼þ18%, P¼ 0.0343), HR (median
HR¼þ27 bpm, P¼ 0.0035) and CI (median
Table 2 MRI was performed at rest and during dobutamine stress in 15 patients with PH and five younger
volunteers. Values are median (interquartile range).
PH patients Younger Volunteers
Rest Stress Rest Stress
Pulmonary artery
AMAX (cm
2) 9.3 (7.1–11.0) 9.6 (7.2–11.5)* 6.8 (6.0–7.9)y 7.1 (6.5–8.0)
AMIN (cm
2) 8.2 (5.9–9.9) 8.3 (6.0–10.7)** 5.2 (3.6–5.7)z 4.1 (3.6–5.0)
RAC (%) 12.6 (9.4–19.2) 11.0 (9.2–16.5) 43.6 (33.1–74.6)z 67.5 (29.4–85.4)#
Right ventricle
SVI (mL/m2) 23 (17–37) 26 (22–34) 47 (44–49)z 52 (49–58)#
EDVI (mL/m2) 98 (68–113) 81 (60–108) 67 (61–87) 64 (58–76)
ESVI (mL/m2) 56 (38–73) 42 (24–54)* 29 (23–42)y 11 (9–22)#
EF (%) 34 (18–43) 40 (23–46)* 67 (52–81)z 85 (82–93)#
CI (L/min/m2) 1.9 (1.5–2.4) 2.8 (2.4–3.5)** 2.9 (2.4–2.9) 5.2 (4.4–5.9)#
HR (bpm) 75 (65–87) 109 (88–121)** 60 (50–66) 87 (84–94)#
Z’vv 0.6 (0.2–0.8) 0.8 (0.4–1.3)** 1.7 (1.0–2.0)
z 4.9 (2.9–5.9)#
AMAX, maximum PA area; AMIN, minimum PA area; RAC, Relative area change; RV, right ventricle; LV, left ventricle; SVI, stroke volume
index; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; EF, ejection fraction; CI, Cardiac Index; HR, heart rate; Z’vv,
RV SV/ESV.
*P< 0.05.
**P< 0.01 (PH Stress vs. Rest).
yP< 0.05.
zP< 0.01 (PH vs. Volunteers at rest).
#P< 0.05 (Volunteers Stress vs. Rest).
Fig. 2 Dobutamine stress-MRI was performed in 15 PH patients and
five younger volunteers. Pulmonary artery RAC was measured at rest
and during stress (a), allowing calculation of RAC (b). In all younger
volunteers (depicted by triangles), RACSTRESS was greater than
RACREST; RAC was therefore positive in all. In PH patients
(depicted by circles) there was no difference in median RACREST
(10.8 [9.1–16.0]%) vs. RACSTRESS (12.8 [10.4–19.8]%, P¼ 0.626) but
responses were variable. RAC was negative in 8/13 evaluable PH
patients. Median RAC was lower in PH patients (2.1 [6.4 – 4.4]%)
than younger volunteers (þ22.9 [12.7–33.9]%; P¼ 0.0002).
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CI¼þ2.3 L/min/m2, P¼ 0.0037) and signiﬁcantly
decreased RVESVI (median RVESVI¼18mL,
P¼ 0.0012).
Prognostic impact of RAC in PH patients
Survival data need to be interpreted with caution in a study
of this size. With this caveat, long-term survival appeared
signiﬁcantly poorer in patients with low RAC, deﬁned by
a RAC below the median value (2.6%) (log-rank Chi
square¼ 4.0, P¼ 0.045), see Fig. 3. The hazard ratio for
death in the low RAC group was 4.46 although the
lower end of the 95% CI was close to 1 (95% CI¼ 1.08–
24.5). In all but one of the better prognosis (higher RAC)
groups, RAC was positive, although the magnitude of this
increase was much lower than that seen in healthy younger
volunteers.
There was no statistically signiﬁcant diﬀerence in survival
between groups dichotomized around median values of
RACREST (log-rank P¼ 0.47) or RACSTRESS (log-rank
P¼ 0.59). Similarly, Z’VVREST, Z’VVSTRESS, and Z’VV
yielded no prognostic information (log-rank P values¼ 0.77,
0.95, and 0.62, respectively). Likewise, MRI-derived RVEF,
RVSVI (at rest or stress), and invasive hemodynamic values
provided no statistically signiﬁcant prognostic information.
Correlates of RAC and ’VV
PH patients. RACREST, RACSTRESS, and RAC were each
correlated against 19 other variables, including resting
hemodynamics and MRI measurements of RV and PA func-
tion Therefore, the adjusted level of signiﬁcance for these
comparisons was P< 0.002. RAC correlated inversely
with AMIN (r¼0.84, P< 0.0006). RAC did not correl-
ate with AMAX or any other data, including those indica-
tive of RV dysfunction (e.g. RVEFREST, RVEF,
RVSVIREST, or RVSVI) or RV-PA coupling (e.g. Z’VV
at rest or stress). There were no statistically signiﬁcant cor-
relations between RACREST or RACSTRESS and resting
hemodynamic data or any correlations with rest or stress
MRI measurements. However, consistent relationships
approaching statistical signiﬁcance were observed between
RACSTRESS and measures of stress RV-PA coupling, as
Z’VV STRESS (r¼ 0.75, P¼ 0.004) and Z’VV (r¼ 0.75,
P¼ 0.005). A similar association, of borderline signiﬁcance
was observed between RACSTRESS and RVEF (r¼ 0.73,
P¼ 0.006).
Z’VVREST, Z’VVSTRESS, and Z’VV were correlated
against 18 other variables, including resting hemodynamics
and MRI measurements of RV and PA function. Therefore,
the adjusted level of signiﬁcance for these comparisons was
P< 0.003. Z’VVREST correlated with RVEFREST (r¼ 0.99,
P< 0.0001) and RVMI (r¼ 0.81, P¼ 0.005). Z’VVSTRESS
correlated less strongly, but still signiﬁcantly with
RVEFSTRESS (r¼ 0.90, P< 0.0001), and with RVMI
(r¼ 0.79, P¼ 0.0007). Z’VV did not correlate signiﬁcantly
with any variable.
Younger volunteers. In younger volunteers, there were no
statistically signiﬁcant relationships identiﬁed between
RACREST, RACSTRESS, RAC, Z’VVREST, Z’VVSTRESS,
and Z’VV and MRI-derived RV measurements. Invasive
hemodynamics were not recorded in younger volunteers.
Discussion
In this study, there was considerable heterogeneity in the
eﬀect of dobutamine stress on RAC (RAC) in 15 patients
with PH (see Fig. 2). This was in contrast to the eﬀect in
younger volunteers, in whom RAC was universally posi-
tive (median RAC¼þ23%). In 8/13 PH patients, RAC
was negative, indicating that the PA became less distensible
during stress. In others, there was a marginal increase, but
this was not of the same magnitude to that seen in younger
volunteers. RAC proved to be the only prognostically sig-
niﬁcant variable in this study but these results must be inter-
preted with caution in a study of this size. Notwithstanding
this, patients with a below median RAC (<2.6%) had a
hazard ratio for death over the ten-year follow-up period of
4.46 (95% CI¼ 1.08–24.5, see Fig. 3). These data provide a
potentially intriguing insight into the pathophysiology of
adverse outcomes in PH from which hypotheses for future
studies can be generated.
Associations with RAC and potential mechanisms
Possible explanations for the potential prognostic import-
ance of RAC can be found in the relationships identiﬁed
between it and other data (Table 3). The only statistically
signiﬁcant correlation identiﬁed, after adjusting for the mul-
tiple comparisons involved, was with AMIN. We found no
association between RAC and AMAX. This suggests that
increasing diastolic PA area (AMIN) during stress was the
Fig. 3 Pulmonary artery RAC was measured at rest and during stress
in 15 patients with PH using ds-MRI. Patients with a below median
change in RAC with stress (RAC<2.6%) had a poorer ten-year
survival relative to patients with an above median RAC. Twelve of
15 patients were included in survival analyses.
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principal reason for the fall in RAC in the poor prognosis
PH subgroup. In the younger volunteer population, this
behavior was not observed. Instead, the systolic area of
the main PA (AMAX) tended to increase, while AMIN
tended to decrease; resulting in a universally positive
RAC. Conversely, in PH patients, both AMAX and AMIN
increased with no overall change in median RAC, but highly
variable RAC in individual patients. The factors respon-
sible for this variation are likely to be complex, and include
the combined eﬀects of PA stiﬀening, RV systolic dysfunc-
tion, and abnormal RV pressure loading.
We identiﬁed consistent trends to association between
RACSTRESS and RV-PA coupling eﬃciency during stress
(Z’VVSTRESS [r¼ 0.75, P¼ 0.004] and Z’VV [r¼ 0.75,
P¼ 0.005]). Although these associations did not reach our
adjusted level of statistical signiﬁcance, they suggest that
increased RV-PA coupling ineﬃciency may be an important
mediator of reducedRAC and might contribute to adverse
outcomes. However, we found no detectable diﬀerences in
coupling eﬃciency (as Z’VV) between the high and low
RAC groups, so cannot draw any deﬁnitive conclusions
in this area. We did ﬁnd that RV-PA coupling eﬃciency was
less tightly correlated to RV systolic function during stress
than at rest, since the correlation coeﬃcient between RVEF
and Z’VV fell from 0.99 to 0.90 (P value for both <0.0001).
This suggests that additional factor(s), likely including prox-
imal PA stiﬀening, may become more inﬂuential under
stress conditions. Importantly, we did not identify any sig-
niﬁcant relationship between RAC and either mean PAPP
or PAPP. Mean PAP is a reﬂection of steady ﬂow conditions
and resistance in the small pulmonary arteries, while PAPP
is linearly correlated with the pulmonary circulation disten-
sibility co-eﬃcient, a.7,22
Translational potential: mechanisms
of stress-induced PA stiffening
Although our data suggest that the principal determinant of
low RAC, and potentially a poorer outcome in this study,
was proximal PA stiﬀening, these ﬁndings are not suﬃcient
to precisely resolve the mechanism(s) involved. A better
understanding from future studies is clearly desirable. If
the prognostic impact of RAC is validated elsewhere,
these mechanisms might be targetable by novel PH therapies
speciﬁc to the proximal PA. Potential mechanisms are dis-
cussed here.
In PH, the distal vasculature is already fully recruited and
distended at rest. Dobutamine stress results in abnormal RV
pressure loading, with pressure-induced stiﬀening of the
proximal arteries and early return of reﬂected pressure
waves with transmission of these forces onto the still-eject-
ing RV.23 This would generate extreme trans-mural diastolic
PAP and an increase in AMIN and may have resulted in the
fall in RAC is some PH patients during stress. An alterna-
tive mechanism would be an inability to increase proximal
vascular tone during stress. Also, thickening and stiﬀening
of the proximal PA could result in a decrease in diastolic
elastic recoil. Remodeling of the PA due to chronic PH
Table 3 MRI was performed at rest and during dobutamine stress in 15 patients with PH and five younger volunteers.
Thirteen 15 PH participants with evaluable RAC are dichotomized around the median (2.6%). Values are median
(range). Statistically significant differences between low and high RAC groups are highlighted.
Low RAC High RAC Younger volunteers
Stress PA
RAC (%) 6.4 (14.6–3.1)* 3.4 (2.1–8.4) 37.2 (21.4–152.0)
AMAX (cm
2) 0.23 (0.53–0.78) 0.32 (0.01–0.54) 0.82 (1.04–1.33)
AMIN (cm
2) 0.67 (0.36–1.09)* 0.04 (0.01–0.52) 0.01 (1.80–0.22)
Stress RV
SVI (%) 2 (21–43) 15 (3–116) 22 (0–43)
EF (%) 1 (25–54) 17 (8–227) 46 (4–62)
HR (%) 51 (30–114) 30 (10–56) 49 (28–89)
RV-PA coupling
Z’vv REST 0.51 (0.11–1.26) 0.46 (0.16–0.89) 1.69 (1.01–2.30)
Z’vv STRESS 0.80 (0.09–2.52) 0.66 (0.21–1.69) 4.86 (2.81–6.13)
Resting hemodynamics
PVR (mmHg/L/min) 11 (8–19) 9.5 (7–23) NR
sPAP (mmHg) 92 (76–132) 70 (38–112) NR
PAPP (mmHg) 61 (52–84) 40 (26–76) NR
MVO2 (%) 63 (60–76) 63 (53–70) NR
PA, pulmonary artery; RV, right ventricle; RAC, relative area change; RV, right ventricle; AMAX; maximum PA area; AMIN, minimum PA
area; SVI, stroke volume index; EF, ejection fraction; HR, heart rate; PVR, pulmonary vascular resistance; sPAP, systolic pulmonary
artery pressure; MVO2, mixed venous oxygen saturation; Z’vv, RV stroke volume/RV end-systolic volume ratio; NR, not recorded.
*P< 0.01 (low RAC vs. high RAC).
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would explain why, even in the presence of a dobutamine-
induced increase in CI, AMIN was unchanged or mildly
increased compared to resting conditions in the PH patients
studied. The relative importance of these mechanisms
should be explored in future studies, which if large enough
might also be able to deﬁne speciﬁc mechanisms in PH
groups. For example, diﬀering biomechanics are highly
plausible in idiopathic PAH versus CTEPH and in sub-
types of CTEPH, but could not be meaningfully explored
in this study.
The influence of RV function
In the current study, we did not observe any statistically
signiﬁcant diﬀerence in RV performance parameters
between low and high RAC sub-groups (Table 3).
However, the numbers involved were small, making mean-
ingful sub-group comparisons diﬃcult. We did observe a
trend towards lower RV function in the poor prognosis,
low RAC group (median RVEF¼ 1% versus 17%;
median RVSVI¼2% versus 15%, see Table 3). These
observations would be in keeping with multiple previous
associations between adverse survival and reduced RV per-
formance in PH.1–3 Detection of a relationship between
RAC and survival, where none is observed with RV par-
ameters, may reﬂect a Type II error due to the small sample
size, but may also indicate that the prognostic impact of the
vascular response to stress (as RAC) exceeds that of the
ventricular response (as RVEF, RVSV). The latter
hypothesis is supported by recent data reported by
Vanderpool et al., which describe a hierarchy of prognostic
biomarkers in PH patients.24 In that study, RV-PA coupling
outperformed RVEF (both measured by MRI) and invasive
hemodynamics in multivariable prognostic models. We did
not perform a multivariable analysis to determine the rela-
tive prognostic value of RAC and RV responses because the
small samples size precludes this. However, we doubt that
any additional prognostic information derived from RAC
would justify the additional cost and burden of ds-MRI in
clinical practice. RV performance is well established as the
primary prognostic tool in PH and can be easily assessed by
resting CMR.14 Instead, the point of this study is primarily
conceptual and hypothesis generating. Speciﬁcally, our data
suggest (but do not prove) that proximal PA function may
be a more important determinant of outcome, or response to
particular PH therapies, than RV function in some PH
patients. The predictive value of vascular response was pre-
viously demonstrated in an MRI pilot study, reported by
Jardim, in which a RAC threshold of 10% diﬀerentiated
responders from non-responders to calcium channel block-
ers with 100% sensitivity and 56% speciﬁcity.25
Comparison with previous studies
Swift et al. recently demonstrated that RACREST was prog-
nostically important in patients with early-stage disease, as
deﬁned by minor elevations in PVR (<4 WU increase) and
normal RV function.13 Although our study was conducted
in patients with more advanced disease (median PVR¼ 10
[8–16]mmHg/L/min, median RVEF¼ 34 [18–43]%), our
ﬁndings are in agreement with this work.
In an earlier study, we reported a non-linear, complex
relationship between PAPP and survival in 67 patients
with PH.7 In that study, although PAPP correlated linearly
with distal pulmonary arterial distensibility, as described by
a, mortality was associated in a non-linear fashion. Patients
with intermediate levels of PAPP had the highest mortality,
likely reﬂecting greater RV dysfunction in that cohort.
Unlike PAPP, RAC may be capable of integrating infor-
mation regarding pulmonary arterial stiﬀening and RV
function in patients with PH, resulting in a linear relation-
ship with survival, similar to that previously reported by
Mahapatra et al. regarding pulmonary arterial capacitance
(RVSV/PAPP).26 Although we found no statistically signiﬁ-
cant diﬀerences in measures of RV performance in RAC
sub-groups (Table 3) a future, larger study would be able to
determine these factors more adequately.
Our results diﬀer from previous literature in that we did
not ﬁnd a correlation between RACREST and invasive PA
pressures, or any prognostic inﬂuence of RACREST. We did,
however, demonstrate a relationship between RAC and
survival. The most likely explanation for this apparent dis-
cordance is the small sample size of the current study. The
previous studies investigating RACREST involved 86
12 and
13413 patients, respectively. It may be that the additional
sensitivity provided by stress imaging allowed detection of
a prognostic relationship with RAC but not RACREST.
We therefore do not believe that our ﬁndings conﬂict with
these earlier studies. Instead, we think it is more likely that
our sample was simply too small to detect the relationships
they observed without stress.
Study limitations
It is essential to interpret the survival data in the current
study with caution given the small sample size. However,
this was necessitated by the relatively low incidence of PH
and the complexity and invasive nature of the measure-
ments. The sample size calculation for the study used data
recorded at rest because no stress data had been published at
that time. However, a post-hoc power calculation using the
actual diﬀerence in median RAC observed between rest
and stress in PH participants indicates that the sample
recruited (n¼ 15) delivered 98.8% power. Nevertheless,
the small sample means it is possible that additional factors
involved in adverse RAC behavior have not been detected,
including a more signiﬁcant impact of RV dysfunction,
which appears possible from our data. A further limitation
is the poor age matching of volunteer and PH populations
(median age of volunteers¼ 33 [31–49] years, PH patient-
s¼ 54 [45–60] years; P¼ 0.013). This reﬂected diﬃculty in
recruiting age-matched normal controls not taking any
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cardiac medications. Nevertheless, it is possible that the dif-
ferences in response to dobutamine between cohorts were
purely due to age. However, this seems unlikely since previ-
ous authors have reported similar diﬀerences in RAC
between PH patients and age matched controls at rest.12,13
Furthermore, we found no diﬀerence in the age of PH
patients with high RAC (48 [43–59] years) versus low
RAC (55 [53–58] years; P¼ 0.227). In addition, there
was no correlation between age and RAC (r¼0.138,
P¼ 0.64) or RACSTRESS (r¼0.135, P¼ 0.645).
Importantly, the poor age matching between PH patients
and volunteers would not aﬀect our conclusions regarding
the inﬂuence of  RAC on survival in the PH cohort.
Conclusions
In this study, low RAC was associated with proximal PA
stiﬀening during dobutamine stress. A low (and frequently
negative) RAC in response to dobutamine was also asso-
ciated with an adverse clinical outcome, although these
results need to be interpreted with caution given the size
of the study. Interestingly, RV performance was not
strongly associated with low RAC, nor predictive of
long-term survival, suggesting that the vascular response
to stress may have more prognostic value than the ventricu-
lar response in some PH patients. A larger, prospective
study is required to validate the potential prognostic
impact of RAC during dobutamine-stress MRI in patients
with PH. If this conﬁrms the data reported here, and better
deﬁnes the biomechanics involved, it may be worth pursuing
disease modifying therapies targeted to the proximal PA
circulation.
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